

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Comparison of the effects of preventive injection of 4 mg and 8 mg Ondansetron doses on pain caused by Etomidate injection in patients under general anesthesia

#### Protocol summary

##### Study aim

Comparison of the effect of preventive injection of 4 mg and 8 mg Ondansetron on pain caused by Etomidate injection

##### Design

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 on 60 patients. Lottery and sealed envelopes are used for randomization.

##### Settings and conduct

This is a randomized double-blind clinical trial that will be performed on 60 patients undergoing general anesthesia with Etomidate at Al-Zahra Hospital in Isfahan; After University Ethics Committee approval and patient satisfaction, patients were randomly assigned to the groups. In each group, the desired intervention is applied and the patient's clinical symptoms are recorded. The person who is performing the intervention would be different from the evaluator and they do not know the type of intervention. In spite of the fact that Patients are aware of the study, they are not aware of the type of intervention so they are all blind.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: ASA class I and II, age 18 to 60 years, general anesthesia candidate with Etomidate and patient informed consent to participate in the study Exclusion criteria: heart disease, psychologic disease and diabetes, allergic to drugs used, addiction

##### Intervention groups

Intervention group A: They receive 4 mg Ondansetron 2 minutes before inducing anesthesia Intervention group B: They receive 8 mg Ondansetron 2 minutes before inducing anesthesia Control group C: They receive 4 ml distilled water 2 minutes before inducing anesthesia, then all three groups will be induced under anesthesia with 20 mg Etomidate, and their clinical signs will be recorded.

#### Main outcome variables

Pain caused by Etomidate

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20160307026950N38**

Registration date: **2021-10-25, 1400/08/03**

Registration timing: **registered\_while\_recruiting**

Last update: **2021-10-25, 1400/08/03**

Update count: **0**

##### Registration date

2021-10-25, 1400/08/03

##### Registrant information

##### Name

Behzad Nazemroaya

##### Name of organization / entity

Isfahan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3212 3543

##### Email address

behzad\_nazem@med.mui.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-10-23, 1400/08/01

##### Expected recruitment end date

2022-01-21, 1400/11/01

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison of the effects of preventive injection of 4 mg and 8 mg Ondansetron doses on pain caused by Etomidate injection in patients under general anesthesia

**Public title**

The effect of Ondansetron on pain caused by Etomidate injection

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients 18 to 60 years Grade I and II in ASA criteria (American Society of Anesthesia) Candidate for general anesthesia with Etomidate

**Exclusion criteria:**

Patients with Heart Disease Patients with Psychologic disease Allergic to drugs used in the study Taking sedatives or painkillers 24 hours before anesthesia Addiction to drugs

**Age**

From **18 years** old to **60 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

This is a simple randomized clinical trial in which patients are entered the study groups by lottery; The medicines and placebo are placed in the sealed, opaque and similar form packets which are coded. Each code is also written on a piece of paper, folded, and placed inside a box. After entering the operating room, each patient takes one of the papers out of the box; The pocket with the same number is the intervention that will apply for him. This process continues till the number of patients will reach the desired one.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

This is a double-blind clinical trial; In this way, before obtaining consent, patients are studied but do not know which group they will be in and therefore are blind. Also, the nurse who injects the drug and the researcher who records the patient's symptoms do not know the type of drug and are blind.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee in Biomedical Research, Isfahan University of Medical Sciences

**Street address**

Hezar Jarib St

**City**

Isfahan

**Province**

Isfahan

**Postal code**

8174673461

**Approval date**

2021-07-01, 1400/04/10

**Ethics committee reference number**

IR.MUI.MED.REC.1399.443

**Health conditions studied****1****Description of health condition studied**

Pain caused by Etomidate

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

The amount of pain caused by Etomidate injection

**Timepoint**

During the injection until 30 seconds

**Method of measurement**

Faces Pain Rating Scale (FPRS)

**Secondary outcomes****1****Description**

Heart Rate

**Timepoint**

Before injection, immediately after injection, 5 and 10 minutes after Etomidate injection and then every 15 minutes until the end of the operation.

## Method of measurement

ECG monitoring

## 2

### Description

Moderate arterial blood pressure

### Timepoint

Before injection, immediately after injection, 5 and 10 minutes after Etomidate injection and then every 15 minutes until the end of the operation.

### Method of measurement

Barometer

## 3

### Description

Arterial blood oxygen saturation

### Timepoint

Before injection, immediately after injection, 5 and 10 minutes after Etomidate injection and then every 15 minutes until the end of the operation.

### Method of measurement

Pulse oximeter

## 4

### Description

Duration of anesthesia

### Timepoint

From the beginning of anesthesia to the end of recovery

### Method of measurement

Clock

## Intervention groups

## 1

### Description

Intervention group A: In this group, eligible patients, after being placed on a surgical bed and monitoring connection, receive 300 ml of normal saline per hour, then they are injected with 4 mg of Ondansetron made by Exir Pharmaceutical Company in 2 minutes and 2 minutes later, they are induced under anesthesia with 20 mg of Etomidate made by Abu Reihan company and the patient's clinical symptoms are recorded.

### Category

Prevention

## 2

### Description

Intervention group B: In this group, eligible patients, after being placed on a surgical bed and monitoring connection, receive 300 ml of normal saline per hour, then they are injected with 8 mg of Ondansetron made by Exir Pharmaceutical Company in 2 minutes and 2 minutes later, they are induced under anesthesia with 20 mg of Etomidate made by Abu Reihan company and the patient's clinical symptoms are recorded.

### Category

Prevention

## 3

### Description

Control group C: In this group, eligible patients, after being placed on a surgical bed and monitoring connection, receive 300 ml of Normal Saline per hour, then they are injected with 4 ml of distilled water and 2 minutes later under anesthesia. With 20 mg of Etomidate made by Abu Reihan company and the patient's clinical symptoms are recorded.

### Category

Placebo

## Recruitment centers

## 1

### Recruitment center

#### Name of recruitment center

Alzahra hospital

#### Full name of responsible person

Behzad Nazemoroaya

#### Street address

Soffeh boulevard, Shahid Keshvari highway

#### City

Isfahan

#### Province

Isfahan

#### Postal code

8174675731

#### Phone

+98 31 3620 2020

#### Email

behzad\_nazem@med.mui.ac.ir

## Sponsors / Funding sources

## 1

### Sponsor

#### Name of organization / entity

Esfahan University of Medical Sciences

#### Full name of responsible person

Shaghayegh Haghjoo

#### Street address

Hezar Jarib

#### City

Isfahan

#### Province

Isfahan

#### Postal code

8174673461

#### Phone

+98 31 3668 0048

#### Email

research@mui.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Esfahan University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Esfahan University of Medical Sciences  
**Full name of responsible person**  
Ruzbeh Akhavanfar  
**Position**  
Medical student  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
General Practitioner  
**Street address**  
Hezar Jarib  
**City**  
Isfahan  
**Province**  
Isfahan  
**Postal code**  
8146713543  
**Phone**  
+98 31 3620 2020  
**Email**  
Roozbeh1372@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Esfahan University of Medical Sciences  
**Full name of responsible person**  
Behzad Nazem roaya  
**Position**  
Professor assistant of Anesthesia and Intensive  
carentensive care  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Anesthesiology  
**Street address**  
Hezar Jarib  
**City**  
Isfahan

**Province**  
Isfahan  
**Postal code**  
8146713543  
**Phone**  
+98 31 3620 2020  
**Email**  
behzad\_nazem@med.mui.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Esfahan University of Medical Sciences  
**Full name of responsible person**  
Leyla Rafiei  
**Position**  
Nurse Anesthetist  
**Latest degree**  
Bachelor  
**Other areas of specialty/work**  
Anesthesiology  
**Street address**  
Hezar Jarib  
**City**  
Isfahan  
**Province**  
Isfahan  
**Postal code**  
8146713543  
**Phone**  
+98 31 3620 2020  
**Email**  
leylarafiei943@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available